Clinical Trials Logo
  1. Home
  2. Refractory Chronic Cough
  3. NCT05600777

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

Refractory Chronic Cough Clinical Trial

Official title:
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study With Open-Label Extension of BLU-5937 in Adult Participants With Refractory Chronic Cough, Including Unexplained Chronic Cough

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Clinical Trial Description

The primary efficacy objective is to assess the effect of BLU-5937 on 24-hour cough frequency in adults with refractory chronic cough (including unexplained chronic cough) at 24 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05600777
Study type Interventional
Source Bellus Health Inc. - a GSK company
Contact US GSK Clinical Trials call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Status Recruiting
Phase Phase 3
Start date January 13, 2023
Completion date June 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03282591 - Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough Phase 2
Completed NCT02476890 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Completed NCT03407014 - Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) Phase 2
Recruiting NCT05599191 - A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 3
Recruiting NCT03662269 - Indomethacin for Refractory Chronic Cough Phase 3
Recruiting NCT05962151 - Refractory Chronic Cough Improvement Via NAL ER (RIVER) Phase 2
Recruiting NCT05110144 - Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough Phase 2
Active, not recruiting NCT04882943 - COllaboration REsearch on Chronic Cough (COREC): a French Multicenter Database
Enrolling by invitation NCT05733533 - A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough Phase 2
Completed NCT02349425 - A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) Phase 2
Completed NCT05628740 - Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175 Phase 1
Not yet recruiting NCT06213363 - A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough Phase 1/Phase 2
Completed NCT02412020 - Treatment of Refractory Chronic Cough With PA101 Phase 2
Completed NCT04678206 - Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough Phase 2
Completed NCT02612623 - An 8-Week Refractory Chronic Cough Study (MK-7264-021) Phase 2
Completed NCT02612610 - A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) Phase 2
Completed NCT02397460 - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) Phase 2
Not yet recruiting NCT05265871 - ATP Level and Cough Sensitivity to ATP in Subjects With Refractory Chronic Cough